Future studies incorporating caplacizumab might provide a broader perspective, particularly in examining its role in managing CTEPH and addressing in situ thrombosis through vWF modulation, a concept we and others have earlier suggested [35,36]. Here, VWF is linked to chronic thromboembolic pulmonary hypertension.